1H2026 Company Update

PT Prodia Widyahusada Tbk | PRDA.JK

Sustainability for Healthy Community

Disclaimer

This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By viewing all or part of this presentation, you agree to maintain confidentiality regarding the information disclosed in this presentation as set out in the confidentiality agreement signed by you and to be bound by the limitations set forth herein. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

This presentation is for information purposes only and does not constitute or form part of an offer, solicitation or invitation of any offer, to buy or subscribe for any securities, nor should it or any part of it from the basis of, or be relied in any connection with, any contract or commitment whatsoever. Any such purchase should be made solely on the basis of the information contained in the final offering memorandum relating to such securities.

Neither this presentation nor any copy of portion of it may be sent or taken, transmitted or distributed, directly or indirectly, in or into Japan, Australia, Canada or the United States or any other jurisdiction which prohibits the same. The securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state of the United States or any other jurisdictions and the securities may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. This presentation is not for distribution in, nor does it constitute an offer for sale of the securities in the United States. The Company does not intend to offer or sell the securities of the Company to the public in the United States. Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company and that would contain detailed information about the Company and management as well as financial statements.

This presentation may not be forwarded or distributed to any other person and may not be copied or reproduced in any manner. Failure to comply with this directive may violate applicable laws.

This presentation includes forward-looking statements. These statements contain the words "anticipate", believe", "intend", "estimate", "expect", "plan" and words of similar meaning. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Company's business and services) are forward-looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company to be materially different from results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on the numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate and must be read together with those assumptions. These forward-looking statements speak only as at the date of this presentation. Predictions, projections or forecasts of the economy or economic trends of the markets are not necessarily indicative of the future or likely performance of the Company. Past performance is not necessarily indicative of future performance.

The information and opinions contained in this presentation noted above are subject to change without notice.

Company Overview

1H2026 Key Highlights

Key Player in Private Independent Clinical Lab chain with 40.0%* market share in Indonesia

Sustainability for Healthy Community

IDR 1.115 Trillion
USD 62.4 Million
1H2026 Revenue (+8.5% YoY)

>1.38 Million
1H2026 Visit (+9.7% YoY)

>9.99 Million
1H2026 Volume (+12.8% YoY)

IDR 77.6 Billion
USD 4.3 Million
1H2026 Net Income (+11.4% YoY)

**data of 2024*

Current Initiatives

Start from 2025, **Prodia expands networks** through strategic collaboration in **SEA Market** and optimalization of **clinical services**

2024 PROLINE
Acquiring 39% shares in **Proline** (The IVD Industry)

Jun 2025 ProSTEM
Acquiring 30% shares in **ProSTEM** (Stem Cell Therapy)

Nov 2025 PCMC
Launch **Prodia Clinical Multiomics Centre (PCMC)**

Feb 2026 Autoimmune & Allergy Clinics by Prodia
Launch **Autoimmune & Allergy Clinic** in Greater Jakarta

Apr 2026 Stemcell Clinic by Prodia
Launch **Stem Cell Clinics by Prodia** in Greater Jakarta



392 Outlets
in 34 Provinces in Indonesia
*[**16 new outlets** opened in 1H2026]*

Continuous Improvement in a Challenging Market

Ensure sustainability business with innovation, growth, and optimization

Visits
(in Million)



Revenue
(in IDR Trillion)



Revenue per Visit
(in IDR '000)



EBITDA
(in IDR Billion)



*covers 5 annual growth periods (2020 → 2025)

Prodia **has strengthen the fundamental** and generated continuous number to **ensure sustainability business**, while there is a bit normalization compared to Pandemic Covid-19 Years

Business Highlight

The Comprehensive Center of Excellence

Delivering personalization and precision in multiple customer segments

Sustainability for Healthy Community

Routine Testing	Non-Laboratory Testing	Specialty Clinics
Esoteric Testing	Referral Lab Services	Doctor Consultation
Multiomics Testing	General Medical Check-Up Services	Preventive Treatment

Walk-In Customers

- Individual Walk-In Patients
- Payment made out-of-pocket

Doctor Referrals

- Patients referred by their doctors
- Payment made out-of-pocket

External Referrals

- Samples referred by other healthcare providers (i.e.: labs, hospitals)
- Patients referred by insurance
- Funded by healthcare providers

Corporate Clients

- Customers whose employers offer them access to diagnostic testing as form of compensation
- Funded by corporate clients and private insurance

One-stop shop, offering the **most comprehensive range of clinical lab tests** in Indonesia, allowing us to meet the needs of a wide range of customers

Scalable Hub and Spoke Business Model

Centralized core operations (hub) while efficiently distributing services through multiple outlets (spokes)

4 Referral Labs in Jakarta, Surabaya, Medan, Makassar

Prodia Referral Lab Services (PRLS)

Prodia Clinical Labs, Hospitals and Other Clinics may refer tests to PRLS

Centralized information with integrated IT platform that connects each lab to PRLS

Collection / Testing

Prodia Clinical Labs & Clinics / Specialty Clinics

Our Regional Referral Labs serves a 24/7 Operation to Fully Accommodate Referral Needs from All Prodia Outlets

Testing

Prodia Clinical Labs

- External Referrals
- Walk-in Customers
- Corporate Clients
- Doctor Referrals

Digital platform for online registration & results

- Point-of-Care
- Doctor Referrals

Digital Diagnostic Partner for doctors to refer testing for their patients, online chat and results

Significant Economies of Scale Achieved

- **Hub and spoke** model offers scalable platform **reducing turnaround time and cost**
- **Spokes** facilitate **deeper penetration within region** strengthening brand and driving higher volumes
- **Efficiency of a clinical laboratory improves** with increasing test volumes making automated tests less expensive and labs more cost efficient

Maintain Strong and Long-Term Relationship

Generate new tests and ongoing referrals in partnership with medical & scientific community

Strong relationships through the work of **more than 500 Marketing and Laboratory Information Service personnel**

Quality Service

Introduced new tests, such as HPV-DNA High Risk Self-Collection (My HPV Test), Maternal Cell Contamination Check (QF-PCR), Panel Arbovirus (Multiplex PCR), ProChromosomal (CMA)

New Test Introduction

Ongoing Referrals

Received referrals from **>34,000 doctors in 1Q2026**

Research Collaboration

Entered into agreement with **56 institutions:** 51 Faculty of Medicines, 1 Faculty of Pharmacy, 1 Faculty of Health Sciences, 1 Institution in Science and Tech., 1 Institution in Molecular Biology, and 1 Professional Organization

Prodia has fostered long-term relationships with healthcare practitioners and medical and scientific community, which **generated an ongoing source of referrals and scientific breakthrough**.

Prodia

Sustainability for Healthy Community

Be The Next Generation Laboratory

To deliver precision medicine with comprehensive lab services

Next Generation Laboratory

- Research Laboratory (Research)
- Evaluation Laboratory (EVALUATION)
- Mass Spectrometry & Separation Science Laboratory (MASS SPECTROMETRY)
- Molecular Predictive & Diagnostic Laboratory (MOLECULAR)
- Anatomical Pathology Laboratory (PATHOLOGY)
- Cancer Molecular Diagnostic
- Advance Immunology & Flowcytometry Laboratory (IMMUNOLOGY)
- Advance Microbiology Laboratory

Bioinformatics Laboratory

The Concept of Precision Medicine

Personalized Treatment and Prevention

- ✔ Global initiative to move towards personalized treatment and prevention
- ✔ Leverages genomics, proteomics, and metabolomics analysis
- ✔ Key to the successful offering of precision medicine is the availability of diagnostic information

Targeted Therapy

Business Updates

Expand Our Presence with Diverse Models

With strategic expansion of outlets, ensuring proximity to our customers

Sustainability for Healthy Community

FY2025



1H2026



Clinical Labs & PHC | POC Outlets | Hospital Labs | Specialty Clinics

**includes 10 (ten) Standalone PHC, and 5 (five) specialty clinics that operate in existing branches: 1) PCHC Jakarta, 2) PWHC Jakarta, 3) PCHC Medan, 4) PWHC Medan, 5) PCHC Surabaya.*
***consists of standalone specialty clinics (PWHC and PSHC Surabaya, and PSHC Jakarta)*

New outlets in 1H2026

16 new POC outlets

Digital Platform Optimization

Available on the App Store
GET IT ON Google Play

U by Prodia
App Development

Available on the App Store
GET IT ON Google Play

Additional Features
in **Prodia for Doctor**

2026 Outlet Development Target

> 3 Hospital Labs Management
includes hospital lab & genomic site

> 20 POC Outlets
Selective and improving existing Point-of-Care

2-3 Clinical Labs
Branch

"Prodia not only focus to develop physical outlets but also the digital network to create **omnichannel presence** for our customers"

Financial Updates

Solid Performance in 1H2026 Revenue

Supported by solid growth across customer segments

Revenue (Unaudited)
In IDR Billion

1H21-1H26 CAGR -2.1%



Quarterly Revenue (Unaudited)
In IDR Billion



1H2026 revenue surpassed 1,115 IDR Bn, highest in the past 4 consecutive years, with 2Q2026 even surpassed the past 5 years along with COVID year, supported by strong growth in External Referrals, Corporate Clients, and Doctor Referrals while Walk-In Customers remained stable

1H2026 Financial Performance

Operational efficiency drives stronger profitability

Cost of Revenue (COR)
in IDR Billion

1H21-1H26 CAGR +0.6%



COR increased by 7.1% YoY driven by higher direct costs and indirect costs, in line with increased operational metrics

Gross Profit
in IDR Billion

1H21-1H26 CAGR -3.9%



Gross profit margin expanded to 56.4%, supported by healthy revenue growth and disciplined cost management.

OPEX
In IDR Billion

1H21-1H26 CAGR +6.1%



OPEX increased by 6.3% YoY driven by higher personnel costs, software maintenance, management fees, and consultant expenses to support ongoing business operations and strategic initiatives.

Net Income
In IDR Billion

1H21-1H26 CAGR -23.8%



Net income rebound to 7.0% margin (+11.4% YoY) reflecting improved profitability

1H2026 Financial Summary

Sustained growth with improving profitability

(in IDR Bn)	1H2026	1H2025	Change
Revenue	1,114.7	1,027.3	+8.5%
Gross Profit	628.3	573.3	+9.6%
EBIT	88.3	63.6	+38.9%
EBT	98.6	86.2	+14.4%
Net Income	77.6	69.6	+11.4%
EPS	87.15	75.88	+14.9%
EBITDA	216.3	202.0	+7.1%

(in IDR Bn)	1H2026	1H2025	Change
Total Asset	2,642.7	2,574.1	+2.7%
Total Equity	2,341.3	2,314.9	+1.1%

Professional Team & Shares Information

Prodia

Sustainability for Healthy Community

Experienced & Professional Management Team

With more than 20 years experience in delivering growth and innovation of Prodia



54 Years of Experience

Andi Wijaya

Co-Founder and Chairman



54 Years of Experience

Gunawan Prawiro Soeharto

Co-Founder and Commissioner

43 Years of Experience

Endang Hoyaranda

Commissioner

39 Years of Experience

Dewi Muliaty

Commissioner

35 Years of Experience

Keri Lestari Dandan

Independent Commissioner

38 Years of Experience

Lukas Setia Atmaja

Independent Commissioner

30 Years of Experience

Liana Kuswandi

President Director

20 Years of Experience

Marina Eka Amalia

Finance & Sustainability Director

30 Years of Experience

Indriyanti Rafi Sukmawati

Commercial & Partnership Director

29 Years of Experience

Andri Hidayat

Integrated Solution & Diagnostics Director

25 Years of Experience

Ida Zuraida

People & Organizational Development Director

Shareholders Composition

Public free float is 26% of total with market cap of IDR 2.13 Trillion*

Sustainability for Healthy Community

- PT Prodia Utama — 57%
- Bio Majesty Pte. Ltd. — 12%
- Public — 26%
- Treasury Stock — 5%

PT Prodia Widyahusada Tbk
Nationwide Outlet Network across Indonesia

The sister companies in Prodia Group:

- PRODIS — Distributor for medical equipment
- Prodia the CRO — Contract Research Organization
- ProSTEM — Research, therapy and banking of stem cell (30%)
- Prodia occupational health institute — Occupational Health Service
- innodia — Distributor for healthcare products
- PROLINE — In Vitro Diagnostics (IVD) Industry (27.3%)

PT Prodia Digital Indonesia (Prodia DIGITAL INDONESIA)
- PT Prodia Widyahusada Tbk — 99%
- Sister companies in Prodia Group — 1%

*data per 30 Jun 2026

Sustainability for Healthy Community

For further Information:

PT Prodia Widyahusada Tbk
Prodia Tower, Jalan Kramat Raya No. 150
Jakarta 10430, Indonesia
Email: **investor.relation@prodia.co.id**